Genomic engineering company Inscripta raises $58M

BOULDER — Inscripta Inc. has raised $58 million in its latest round of fundraising as it continues on the path of commercializing its gene-editing platform. 

The Boulder-based Inscripta raised the funds from seven investors, including one who purchased $8.06 million in options to buy stock in the future, according to disclosures to the U.S. Securities and Exchange Commission Monday.

The company has now raised north of $259 million from venture capital sources since its founding in 2015, including a $125 million Series D round late last year as it aimed to start selling its platform.

SPONSORED CONTENT

Business Cares: April 2024

In Colorado, 1 in 3 women, 1 in 3 men and 1 in 2 transgender individuals will experience an attempted or completed sexual assault in their lifetime. During April, we recognize Sexual Assault Awareness Month with the hopes of increasing conversations about this very important issue.

Genomic engineering, also known as “gene editing,” is the process of adding or removing certain parts of a living organism’s genetic blueprint and purposefully creating mutations. The process could be used to cure genetically-driven diseases such as cancer, but remains the center of a larger debate over medical ethics of manipulating the human genome.

Inscripta’s round comes days after fellow Boulder-based biotechnology firm SomaLogic Inc. raised $121 million in its Series A, setting a record for the largest-single venture capital round in the area this year.

The company did not respond to a request for comment Monday afternoon.

© 2020 BizWest Media LLC